AVIR
Aviragen Therapeutics, IncNASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Thu, Nov. 3, 4:27 PM
    • Aviragen Therapeutics (NASDAQ:AVIR): FQ1 EPS of -$0.26 beats by $0.02.
    • Revenue of $0.1M (-94.1% Y/Y) misses by $0.47M.
    • Press Release
    | Thu, Nov. 3, 4:27 PM
  • Wed, Sep. 14, 4:04 PM
    • Aviragen Therapeutics (NASDAQ:AVIR): FQ4 EPS of -$0.18
    • Revenue of $0.6M (-85.4% Y/Y)
    • Press Release
    | Wed, Sep. 14, 4:04 PM
  • Fri, Jul. 15, 7:10 AM
    • Achillion Pharmaceuticals (NASDAQ:ACHN) initiated with Sell rating and $4 (54% downside risk) price target by Chardan Capital.
    • Rigel Pharmaceuticals (NASDAQ:RIGL) initiated with Buy rating and $6 (182% upside) price target by H.C. Wainwright.
    • Aviragen Therapeutics (NASDAQ:AVIR) initiated with Buy rating and $5 (178% upside) price target by H.C. Wainwright.
    • Incyte (NASDAQ:INCY) initiated with Outperform rating by Berenberg.
    • TearLab (NASDAQ:TEAR) initiated with Buy rating and $2 (167% upside) price target by Rodman & Renshaw.
    • AstraZeneca (NYSE:AZN) initiated with Hold rating by Argus Research.
    • Spark Therapeutics (NASDAQ:ONCE) initiated with Outperform rating and $70 (32% upside) price target by RBC Capital.
    • Akari Therapeutics (NASDAQ:AKTX) initiated with Sell rating and $5 (55% downside risk) price target by Chardan Capital.
    | Fri, Jul. 15, 7:10 AM | 2 Comments
  • Thu, May 5, 5:26 PM
    • Aviragen Therapeutics (NASDAQ:AVIR): FQ3 EPS of -$0.14 beats by $0.04.
    • Revenue of $5.3M (-10.2% Y/Y) beats by $3.5M.
    | Thu, May 5, 5:26 PM
  • Tue, Apr. 26, 7:44 AM
    • Aviragen Therapeutics (NASDAQ:AVIR), formerly Biota Pharmaceuticals, raises $20M in new capital via the sale of a portion of the royalty rights to Inavir to HealthCare Royalty Partners. It intends to use the proceeds to advance its pipeline of direct-acting antivirals to treat infections that have limited treatment options.
    • Inavir, an inhaled neuraminidase inhibitor approved in Japan for the treatment and prevention of influenza, is the leading flu treatment there. It is marketed by Daiichi Sankyo (OTCPK:DSKYF)(OTCPK:DSNKY).
    | Tue, Apr. 26, 7:44 AM
  • Tue, Apr. 12, 7:09 AM
    • Citing the transition of its business from drug discovery and early-stage licensing to drug development with late-stage product candidates, Biota Pharmaceuticals (NASDAQ:BOTA) changes its name to Aviragen Therapeutics. Trading under the new symbol "AVIR" will commence tomorrow.
    | Tue, Apr. 12, 7:09 AM
  • Thu, Mar. 17, 6:47 AM
    • Biota Pharmaceuticals (NASDAQ:BOTA) completes the sale of its broad spectrum antibiotic program to a subsidiary of Cambridge, MA-based Spero Therapeutics, LLC for an undisclosed sum. The company intends to focus its resources on its clinical-stage antiviral programs.
    | Thu, Mar. 17, 6:47 AM
  • Tue, Feb. 16, 10:43 AM
    • The FDA designates Biota Pharmaceuticals' (BOTA +10.6%) antiviral candidate, BTA585, for Fast Track review for the treatment of respiratory syncytial virus (RSV) infections. RSV is a major cause of upper and lower respiratory tract infections in infants, children and young adults.
    • BTA585 is an oral RSV fusion inhibitor that fights RSV infection by interfering with the fusion of the viral envelope to the cell membrane of the host cell.
    • Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the New Drug Application (NDA).
    | Tue, Feb. 16, 10:43 AM
  • Fri, Feb. 5, 7:44 AM
    • Biota Pharmaceuticals (BOTA) FQ2 results: Revenues: $1.7M (-87.8%); R&D Expense: $6.3M (+31.3%); SG&A: $2.1M (-19.2%); Net Loss: ($6.5M) (-200.0%); Loss Per Share: ($0.17) (-189.5%); Quick Assets: $52M (-9.7%).
    • No guidance given.
    | Fri, Feb. 5, 7:44 AM
  • Fri, Feb. 5, 7:03 AM
    • Biota Pharmaceuticals (NASDAQ:BOTA): FQ2 EPS of -$0.17
    • Revenue of $1.7M (-87.8% Y/Y)
    | Fri, Feb. 5, 7:03 AM
  • Dec. 7, 2015, 12:48 PM
    | Dec. 7, 2015, 12:48 PM
  • Nov. 6, 2015, 7:02 AM
    • Biota Pharmaceuticals (NASDAQ:BOTA): FQ1 EPS of -$0.17
    • Revenue of $1.7M (+142.9% Y/Y)
    | Nov. 6, 2015, 7:02 AM
  • Nov. 2, 2015, 11:41 AM
    • Biota Pharmaceuticals (BOTA +1.6%) appoints Mark Colonnese as EVP and Chief Financial Officer effective immediately. He joins the firm from Stealth BioTherapeutics where he was CFO.
    | Nov. 2, 2015, 11:41 AM
  • Sep. 11, 2015, 7:15 AM
    • Biota Pharmaceuticals (BOTA +0.5%) FQ4 results: Revenues: $4.1M (-51.8%); R&D Expense: $5.2M (-17.5%); SG&A: $1.3M (-40.9%); Operating Loss: ($20M) (--90.5%); Net Loss: ($19.9M) (-95.1%); Loss Per Share: ($0.55) (-89.7%).
    • FY2015 results: Revenues: $24.6M (-64.2%); COGS: $3.6M (-93.0%); R&D Expense: $19.8M (+13.1%); SG&A: $9.4M (-7.8%); Operating Loss: ($19.5M) (-69.6%); Net Loss: ($19.1M) (-73.6%); Loss Per Share: ($0.54) (-54.3%); Quick Assets: $57.6M (-29.5%).
    • No guidance given.
    | Sep. 11, 2015, 7:15 AM
  • Sep. 11, 2015, 7:03 AM
    • Biota Pharmaceuticals (NASDAQ:BOTA): FQ4 EPS of -$0.55
    • Revenue of $4.1M (-51.8% Y/Y)
    | Sep. 11, 2015, 7:03 AM
  • May 7, 2015, 7:07 AM
    • Biota Pharmaceuticals (NASDAQ:BOTA): FQ3 EPS of $0.03
    • Revenue of $5.9M (-80.0% Y/Y) misses by $2.95M.
    | May 7, 2015, 7:07 AM